Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

被引：69

作者：

Dickinson, Michael

Ritchie, David ^{[2
]}

DeAngelo, Daniel J. ^{[3
]}

Spencer, Andrew ^{[4
]}

Ottmann, Oliver G. ^{[5
]}

Fischer, Thomas ^{[6
]}

Bhalla, Kapil N. ^{[7
]}

Liu, Angela ^{[8
]}

Parker, Katie ^{[8
]}

Scott, Jeffrey W. ^{[8
]}

Bishton, Mark

Prince, H. Miles ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Haematol Serv, Melbourne, Vic 3002, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Alfred Hosp, Clin Haematol & BMT, Melbourne, Vic, Australia

[5] Goethe Univ Frankfurt, Med Klin 2, Frankfurt, Germany

[6] Otto VonGuericke Univ Magdegurg, Dept Hematol & Oncol, D-39016 Magdeburg, Germany

[7] Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA

[8] Novartis Oncol, Florham Pk, NJ USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 147卷 / 01期

关键词：

Hodgkin lymphoma; HDAC inhibitor; LBH589; panobinostat; HISTONE; CELLS;

D O I：

10.1111/j.1365-2141.2009.07837.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P>There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by <SU18</SUF-fluoro-2-deoxy-d- glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.

引用

页码：97 / 101

页数：5

共 15 条

[1]

Andrew Spencer MP, 2007, BLOOD, V110, pA907

[2] Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells [J].